U.S. National Institutes of Health Recommend to Expand Its Scope of Research in the Development of Pluristem's PLX-RAD Cells for the Treatment of Acute Radiation Syndrome
Pluristem Therapeutics Inc, a leading developer of placenta-based cell therapies, announced today that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, has recommended to Pluristem that NIAID expand the scope of its ongoing animal research using PLX-RAD cells for the treatment of acute radiation syndrome (ARS).
View full press release